Aggressive Periodontitis ; diagnosis ; therapy ; Humans

Aggressive Periodontitis ; therapy ; Humans ; Periodontics ; methods

OBJECTIVE: To evaluate the survival rate and peri-implant clinical parameters of Locking-Taper implants in patients having lost their teeth due to non-periodontitis (NP) reasons, chronic periodontitis (CP) and aggressive periodontitis (AgP). METHODS: In the study, 145 subjects were installed with 315 Bicon Locking-Taper implants and followed up for 1-5 years. The subjects and implants were classified into three groups, tooth loss by NP, CP and AgP. NP included 44 subjects with 100 implants, CP 70 subjects with 132 implants and AgP 31 subjects with 83 implants. Periodontal parameters before subgingival scaling and root planning (T0), at the end of active periodontal therapy (T1) and at the time of last recall (T2) were recorded. Right after the installation of final restoration and at the time of last recall (T2), peri-implant probing parameters were recorded. RESULTS: After active periodontal therapy, mean probing depth (PD) in CP and AgP were reduced from 4.05 mm, 5.20 mm at T0 to 3.07 mm, 2.96 mm at T1 (P<0.001, P<0.001), (PD≥6 mm)% were reduced from 33.2%, 58.5% at T0 to 14.4%, 10.5% at T1 (P<0.001, P<0.001). The periodontal parameters remained stable at T2 compared with T1 (P>0.05). Cumulative survival rates of implants in NP, CP and AgP were 100%, 97.6% and 100% for 1-5 years' follow-ups with no statistical significance found. At T2, mean implant PD was 2.78 mm, 2.96 mm and 2.97 mm in NP, CP and AgP, with NP significantly lower than the other two groups (P=0.006, P=0.01). The percentage of implant sites with PD≥6 mm was 3.7% in CP and 4.8% in AgP, both significantly higher than NP (P=0.003, P<0.001). 8.4% implant sites showed at least 2 mm deeper than those at prosthesis installation were found in CP group, significantly higher than NP (4.3%, P=0.003). CONCLUSION Periodontal conditions of patients having lost their teeth for chronic and aggressive periodontitis were significantly improved after active periodontal therapy and remained stable during 1-5 years. Short-term survival rates of Locking-Taper implants in patients treated for CP and AgP was no less than those who lost their teeth for non-periodontitis reasons. More sites with increasing peri-implant probing depth were found in CP and AgP patients, compared with NP.
Aggressive Periodontitis/therapy* ; Chronic Periodontitis ; Dental Implants ; Dental Scaling ; Humans ; Periodontal Index ; Tooth Loss ; Treatment Outcome

Adult ; Aggressive Periodontitis ; diagnosis ; diagnostic imaging ; therapy ; Combined Modality Therapy ; Dental Scaling ; Female ; Humans ; Orthodontics, Corrective ; Radiography ; Tooth Loss ; diagnosis ; diagnostic imaging ; therapy

Adult ; Aggressive Periodontitis ; diagnosis ; diagnostic imaging ; therapy ; Combined Modality Therapy ; Dental Scaling ; Female ; Follow-Up Studies ; Guided Tissue Regeneration, Periodontal ; Humans ; Radiography, Panoramic ; Young Adult

OBJECTIVETo evaluate the short term clinical results of scaling and root planning (SRP) only, SRP combined with amoxicillin (AMX) and metronidazole (MTZ) after supragingival scaling or after SRP in the treatment of aggressive periodontitis (AgP).

METHODSA total of 45 patients with AgP were randomly divided into SRP group, SRP with AMX + MTZ after supragingival scaling group and AMX + MTZ after SRP group. Subgingival scaling and root planning were performed one week after supragingival scaling and finished within 1 month. AMX and MTZ were given for 7 days immediately after supragingival scaling or the last time of SPR. Clinical examinations including probing depth (PD), attachment level (AL) and bleeding index (BI) were performed at baseline and 8 weeks after non-surgical periodontal treatment by the same examiner.

RESULTSThere were more PD reduction and AL gain in both AMX + MTZ after supragingival scaling group and AMX + MTZ after SRP group compared with SRP group [2.5 (1.8, 3.3) mm, 2.3 (1.9, 2.7) mm vs. 1.8 (1.3, 2.1) mm, P < 0.05]; [0.9 (0.5, 1.4) mm, 0.8 (0.4, 1.3) mm vs. 0.4 (0.2, 1.0) mm, P < 0.05]. In sites PD ≥ 7 mm, PD reduction was more in AMX + MTZ after supragingival scaling group than AMX + MTZ after SRP group [4.0 (3.0, 5.0) mm vs. 4.0 (3.0, 4.0) mm, P < 0.05)].

CONCLUSIONSThe combined use of AMX and MTZ during non-surgical periodontal treatment for patients with AgP was effective in short term. In patients with most sites PD ≥ 7 mm, AMX and MTZ could be taken after supragingival scaling, but the long-term clinical effects needs further investigation.

Adult ; Aggressive Periodontitis ; drug therapy ; therapy ; Amoxicillin ; therapeutic use ; Anti-Bacterial Agents ; therapeutic use ; Anti-Infective Agents ; therapeutic use ; Combined Modality Therapy ; Dental Scaling ; Drug Therapy, Combination ; Female ; Humans ; Male ; Metronidazole ; therapeutic use ; Root Planing ; Time Factors ; Young Adult

Adult ; Aggressive Periodontitis ; drug therapy ; therapy ; Amoxicillin ; therapeutic use ; Anti-Bacterial Agents ; therapeutic use ; Anti-Infective Agents ; therapeutic use ; Combined Modality Therapy ; Dental Scaling ; Denture, Partial, Fixed ; Humans ; Male ; Metronidazole ; therapeutic use ; Periodontal Abscess ; drug therapy ; therapy ; Root Canal Therapy ; Tooth Extraction ; Toothbrushing

Adult ; Aggressive Periodontitis ; complications ; drug therapy ; therapy ; Anti-Infective Agents ; therapeutic use ; Antirheumatic Agents ; therapeutic use ; Arthritis, Rheumatoid ; complications ; drug therapy ; Dental Scaling ; Female ; Follow-Up Studies ; Humans ; Isoxazoles ; therapeutic use ; Methotrexate ; therapeutic use ; Metronidazole ; therapeutic use ; Periodontal Splints ; Root Canal Therapy ; Spiramycin ; therapeutic use